Alpha Cancer Technologies
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200-101 College St, Toronto, Ontario, M5...Phone Number
(416) 826-6626Website
www.alpha-cancer.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Alpha Cancer Technologies
Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company focused on developing innovative therapies in immuno-oncology, radiopharmaceuticals, and immunomodulation. The company's drug products utilize its patented recombinant human alpha fetoprotein (AFP or ACT-101) to target cancer and autoimmune diseases. ACT has demonstrated safety in over 300 patients and is advancing its proprietary platforms through various pre-clinical and clinical studies. The company aims to provide effective treatments for a range of cancers and autoimmune conditions, supported by seasoned leadership and strategic partnerships.Explore more
Alpha Cancer Technologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alpha Cancer Technologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Alpha Cancer Technologies had a recent Job posting/layoffs
Check out if Alpha Cancer Technologies is spiking on competitors!
Earning: See what the market has to say on Alpha Cancer Technologies recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Alpha Cancer Technologies launches new products
Congratulate Masked Content for being promoted to Masked Content at Alpha Cancer Technologies
Alpha Cancer Technologies, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Alpha Cancer Technologies has new funding data
Check if Alpha Cancer Technologies has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Alpha Cancer Technologies
Compare insights from companies similar to Alpha Cancer Technologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alpha Cancer Technologies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alpha Cancer Technologies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alpha Cancer Technologies.
Alpha Cancer Technologies Tech Stack
A closer look at the technologies used by Alpha Cancer Technologies
See more technologies
Alpha Cancer Technologies News & Media
Alpha Cancer Technologies (ACT) Publishes Pre-Clinical Study Results in Cancer Cell International Demonstrating Excellent Safety and Significant Anti-Tumor Activity from the Company’s Next Generation ADC, ACT-903
TORONTO--(BUSINESS WIRE)-- #ACT903--ACT Publishes Pre-Clinical Study Results Demonstrating Excellent Safety and Significant Anti-Tumor Activity from the Company’s Next-Gen ADC, ACT-903Alpha Cancer Technologies Inc. Presents New Data from ACT-903 in Online Publication at the 2022 ASCO Annual Meeting
In a COLO-205 xenograft model, ACT-903 demonstrates tumor suppression, increased survival after single and multiple doses, and no signs of toxicity TORONTO, CANADA, May 26, 2022 /EINPresswire.com/ -- Alpha Cancer Technologies Inc. (ACT) a …Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting
TORONTO--(BUSINESS WIRE)--Alpha Cancer Technologies Inc. Presents New Data from ACT-903 at 2021 European Society of Medical Oncology Annual MeetingAlpha Cancer Technologies to License AbSci's SoluPro Strain for the Expression of Alpha-Fetoprotein
VANCOUVER, Wash., July 21, 2020 /PRNewswire/ -- AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing of difficult-to-produce biotherapeutics, today announced that it has entered into an agreement to license its E....
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alpha Cancer Technologies
Sign Up For FreeTo access detailed company insights
Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company focused on developing innovative therapies in immuno-oncology, radiopharmaceuticals, and immunomodulation. The company's drug products utilize its patented recombinant human alpha fetoprotein (AFP or ACT-101) to target cancer and autoimmune diseases. ACT has demo... Read More
